Novartis AG ADR (NVS)vsTrinity Biotech plc (TRIB)
NVS
Novartis AG ADR
$148.38
-0.55%
HEALTHCARE · Cap: $273.77B
TRIB
Trinity Biotech plc
$0.70
-4.26%
HEALTHCARE · Cap: $13.77M
Smart Verdict
WallStSmart Research — data-driven comparison
Novartis AG ADR generates 129118% more annual revenue ($56.58B vs $43.78M). NVS leads profitability with a 23.9% profit margin vs -85.4%. TRIB appears more attractively valued with a PEG of 0.30. NVS earns a higher WallStSmart Score of 49/100 (D+).
NVS
Hold49
out of 100
Grade: D+
TRIB
Avoid29
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-62.1%
Fair Value
$91.39
Current Price
$148.38
$56.99 premium
Margin of Safety
+74.2%
Fair Value
$3.19
Current Price
$0.70
$2.49 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Every $100 of equity generates 35 in profit
Strong operational efficiency at 30.5%
Keeps 24 of every $100 in revenue as profit
Generating 2.9B in free cash flow
Growing faster than its price suggests
Conservative balance sheet, low leverage
Areas to Watch
Grey zone — moderate risk
Elevated debt levels
Expensive relative to growth rate
Revenue declined 0.7%
Smaller company, higher risk/reward
Weak financial health signals
ROE of -1913.0% — below average capital efficiency
Revenue declined 5.5%
Comparative Analysis Report
WallStSmart ResearchBull Case : NVS
The strongest argument for NVS centers on Market Cap, Return on Equity, Operating Margin. Profitability is solid with margins at 23.9% and operating margin at 30.5%.
Bull Case : TRIB
The strongest argument for TRIB centers on PEG Ratio, Debt/Equity. PEG of 0.30 suggests the stock is reasonably priced for its growth.
Bear Case : NVS
The primary concerns for NVS are Altman Z-Score, Debt/Equity, PEG Ratio.
Bear Case : TRIB
The primary concerns for TRIB are Market Cap, Piotroski F-Score, Return on Equity.
Key Dynamics to Monitor
NVS profiles as a declining stock while TRIB is a turnaround play — different risk/reward profiles.
TRIB carries more volatility with a beta of 0.93 — expect wider price swings.
NVS is growing revenue faster at -0.7% — sustainability is the question.
NVS generates stronger free cash flow (2.9B), providing more financial flexibility.
Bottom Line
NVS scores higher overall (49/100 vs 29/100), backed by strong 23.9% margins. TRIB offers better value entry with a 74.2% margin of safety. Both earn "Hold" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Novartis AG ADR
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Novartis AG researches, develops, manufactures and markets medical devices worldwide. The company is headquartered in Basel, Switzerland.
Visit Website →Trinity Biotech plc
HEALTHCARE · MEDICAL DEVICES · USA
Trinity Biotech plc acquires, develops, manufactures and markets medical diagnostic products for the clinical laboratory and point of care (POC) segments of the diagnostic market in the United States, Africa, Asia and Europe. The company is headquartered in Bray, Ireland.
Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?